文献速递新药、器械与细胞基因治疗研发临床试验与 GCP

双SGLT1/2抑制剂索格列净治疗1型糖尿病的疗效与安全性:随机对照试验的Meta分析

Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
PubMed 文献 · BMJ · 2019-04-09

该Meta分析纳入6项随机安慰剂对照试验(n=3238,疗程4-52周),评估索格列净治疗1型糖尿病的疗效与安全性。索格列净改善糖化血红蛋白(加权均数差-0.34%)及多项血糖指标,降低低血糖发生率,但增加酮酸中毒(相对危险度3.93)、生殖道感染等风险。

要点

  • 索格列净降低糖化血红蛋白(加权均数差-0.34%,95%CI -0.41%至-0.27%,P<0.001)并改善血糖在目标范围内时间(加权均数差9.73%)。
  • 索格列净增加酮酸中毒风险(相对危险度3.93,95%CI 1.94至7.96)及生殖道感染、腹泻和容量不足事件。
  • 索格列净400 mg/日剂量在多数结局上改善优于200 mg/日剂量,且未增加不良事件风险。

核心结论

  • 在1型糖尿病中,索格列净改善血糖及非血糖结局,降低低血糖发生率和严重低血糖。
  • 通过适当患者选择和基础胰岛素剂量下调可最小化糖尿病酮酸中毒风险。

研究设计与样本

  • 随机对照试验的Meta分析,检索Medline、Cochrane图书馆、Embase、国际会议摘要、临床试验注册库及美欧日监管机构网站至2019年1月10日。
  • 纳入6项随机安慰剂对照试验,共3238例年龄大于18岁的1型糖尿病患者,疗程4-52周。
  • 采用随机效应模型合并主要结局,使用GRADE方法总结证据强度。

主要发现

  • 索格列净降低糖化血红蛋白(加权均数差-0.34%,95%CI -0.41%至-0.27%,P<0.001)、空腹血糖(-16.98 mg/dL,95%CI -22.1至-11.9)及餐后2小时血糖(-39.2 mg/dL,95%CI -50.4至-28.1)。
  • 索格列净降低每日总胰岛素剂量(-8.99%,95%CI -10.93%至-7.05%)、基础胰岛素剂量(-8.03%,95%CI -10.14%至-5.93%)及餐时胰岛素剂量(-9.14%,95%CI -12.17%至-6.12%)。
  • 索格列净改善血糖在目标范围内时间(加权均数差9.73%,95%CI 6.66%至12.81%)及其他连续血糖监测参数,降低体重(-3.54%,95%CI -3.98%至-3.09%)、收缩压(-3.85 mm Hg,95%CI -4.76至-2.93)及白蛋白尿(白蛋白与肌酐比值-14.57 mg/g,95%CI -26.87至-2.28)。
  • 索格列净降低低血糖(加权均数差-9.09事件/患者年,95%CI -13.82至-4.36)和严重低血糖(相对危险度0.69,95%CI 0.49至0.98),但增加酮酸中毒(相对危险度3.93,95%CI 1.94至7.96)、生殖道感染(3.12,95%CI 2.14至4.54)、腹泻(1.50,95%CI 1.08至2.10)和容量不足事件(2.19,95%CI 1.10至4.36)风险。
  • 初始糖化血红蛋白和基础胰岛素剂量调整与糖尿病酮酸中毒风险相关;索格列净400 mg/日剂量在多数血糖及非血糖结局上改善优于200 mg/日剂量,且未增加不良事件风险。

关键数值与推荐

  • 主要结局证据质量高至中等,但主要不良心血管事件和全因死亡证据质量低。
  • 试验疗程相对较短,无法评估长期结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 试验疗程相对较短,无法评估长期结局。
  • 主要不良心血管事件和全因死亡的证据质量低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy and safety of dual sodium glucose cotransporter (SGLT) 1/2 inhibitor sotagliflozin in type 1 diabetes mellitus. DESIGN: Meta-analysis of randomised controlled trials. DATA SOURCES: Medline; Cochrane Library; Embase; international meeting abstracts; international and national clinical trial registries; and websites of US, European, and Japanese regulatory authorities, up to 10 January 2019. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials evaluating the effect of sotagliflozin versus active comparators or placebo on glycaemic and non-glycaemic outcomes and on adverse events in type 1 diabetes in participants older than 18. Three reviewers extracted data for study characteristics, outcomes of interest, and risk of bias and summarised strength of evidence using the grading of recommendations assessment, development, and evaluation approach. Main outcomes were pooled using random effects models. RESULTS: Of 739 records identified, six randomised placebo controlled trials (n=3238, duration 4-52 weeks) were included. Sotagliflozin reduced levels of glycated haemoglobin (HbA1c; weighted mean difference -0.34% (95% confidence interval -0.41% to -0.27%), P<0.001); fasting plasma glucose (-16.98 mg/dL, -22.1 to -11.9; 1 mg/dL=0.0555 mmol/L) and two hour-postprandial plasma glucose (-39.2 mg/dL, -50.4 to -28.1); and daily total, basal, and bolus insulin dose (-8.99%, -10.93% to -7.05%; -8.03%, -10.14% to -5.93%; -9.14%, -12.17% to -6.12%; respectively). Sotagliflozin improved time in range (weighted mean difference 9.73%, 6.66% to 12.81%) and other continuous glucose monitoring parameters, and reduced body weight (-3.54%, -3.98% to -3.09%), systolic blood pressure (-3.85 mm Hg, -4.76 to -2.93), and albuminuria (albumin:creatinine ratio -14.57 mg/g, -26.87 to -2.28). Sotagliflozin reduced hypoglycaemia (weighted mean difference -9.09 events per patient year, -13.82 to -4.36) and severe hypoglycaemia (relative risk 0.69, 0.49 to 0.98). However, the drug increased the risk of ketoacidosis (relative risk 3.93, 1.94 to 7.96), genital tract infections (3.12, 2.14 to 4.54), diarrhoea (1.50, 1.08 to 2.10), and volume depletion events (2.19, 1.10 to 4.36). Initial HbA1c and basal insulin dose adjustment were associated with the risk of diabetic ketoacidosis. A sotagliflozin dose of 400 mg/day was associated with a greater improvement in most glycaemic and non-glycaemic outcomes than the 200 mg/day dose, without increasing the risk of adverse events. The quality of evidence was high to moderate for most outcomes, but low for major adverse cardiovascular events and all cause death. The relatively short duration of trials prevented assessment of long term outcomes. CONCLUSIONS: In type 1 diabetes, sotagliflozin improves glycaemic and non-glycaemic outcomes and reduces hypoglycaemia rate and severe hypoglycaemia. The risk of diabetic ketoacidosis could be minimised by appropriate patient selection and down-titration of the basal insulin dose.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Musso G, Gambino R, Cassader M, et al. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2019. PMID: 30967375. doi:10.1136/bmj.l1328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。